Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) FCF Margin: 2016-2025

Historic FCF Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to 47.69%.

  • Akebia Therapeutics' FCF Margin rose 6559.00% to 47.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.30%, marking a year-over-year decrease of 24705.00%. This contributed to the annual value of -25.40% for FY2024, which is 20844.00% up from last year.
  • Akebia Therapeutics' FCF Margin amounted to 47.69% in Q3 2025, which was up 34.10% from 35.57% recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' FCF Margin ranged from a high of 69.39% in Q3 2022 and a low of -135.37% during Q1 2021.
  • Over the past 3 years, Akebia Therapeutics' median FCF Margin value was -17.05% (recorded in 2023), while the average stood at -9.39%.
  • In the last 5 years, Akebia Therapeutics' FCF Margin tumbled by 16,057bps in 2021 and then surged by 18,481bps in 2022.
  • Akebia Therapeutics' FCF Margin (Quarterly) stood at -108.90% in 2021, then skyrocketed by 1,087bps to -98.02% in 2022, then surged by 9,982bps to 1.80% in 2023, then tumbled by 1,141bps to -9.61% in 2024, then soared by 6,559bps to 47.69% in 2025.
  • Its last three reported values are 47.69% in Q3 2025, 35.57% for Q2 2025, and -23.73% during Q1 2025.